The CROWN study is a global, open-label, randomised, multicentre Phase 3 trial comparing the efficacy and safety of LORVIQUA® against crizotinib in treatment-naïve ALK+ advanced NSCLC patients.1-3
Study design and patient populations for the Phase 3 CROWN Study.
Outcomes for the primary endpoint of progression-free survival (assessed by BICR) and key secondary endpoints.
Outcomes for the secondary endpoint of patient-reported quality of life.
Safety profile of LORVIQUA® in the CROWN Study.
ALK: anaplastic lymphoma kinase, BICR: blinded independent central review, DOR: duration of response, IC: intracranial, NSCLC: non-small cell lung cancer, ORR: objective response rate, OS: overall survival, PFS: proression-free survival
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024